Human papillomavirus infections manifest clinically as benign epithelial proliferations known as cutaneous verrucae or warts. While local cellular immune responses dictate viral control, systemic cytokine dynamics remain incompletely understood. Recent medical research highlights the significance of host T helper 17 pathway activity during active infection. Specifically, evaluating systemic interleukin levels offers crucial insights into disease immunopathogenesis. Investigating serum markers like IL-23 in cutaneous verrucae provides clinicians with a clearer understanding of how systemic inflammation influences localized viral clearance. This comprehensive review examines recent clinical findings regarding serum cytokine alterations in patients affected by recalcitrant or common verrucae.

Understanding the Immunopathogenesis of Cutaneous Verrucae

Cutaneous verrucae represent common epidermal manifestations caused by distinct serotypes of the human papillomavirus. Epidermal keratinocytes serve as primary targets for viral entry, initiating local cellular alterations and hyperplastic tissue growth. Effective viral clearance depends heavily on coordinated host immune mechanisms, particularly cell-mediated immunity. When local immune defenses fail to eliminate infected keratinocytes, persistent clinical lesions develop across various anatomical sites, including palmoplantar and anogenital regions. Consequently, understanding cytokine networks becomes essential for unraveling host-pathogen interactions. T helper cells secrete specialized signaling proteins that coordinate both localized epidermal defenses and broader systemic inflammatory responses. Historically, research primarily emphasized classical T helper 1 (Th1) and T helper 2 (Th2) pathways during viral infections. However, accumulating clinical evidence suggests that the T helper 17 (Th17) axis actively participates in cutaneous antiviral immunity. Cytokines within this pathway regulate mucosal integrity, neutrophilic recruitment, and epidermal barrier homeostasis. Therefore, characterizing systemic cytokine profiles in patients suffering from verrucous lesions provides valuable diagnostic perspective on host immunocompetence and persistent viral infection dynamics.

Investigating the Role of IL-23 in Cutaneous Verrucae

Interleukin-23 serves as a pivotal upstream regulatory cytokine that promotes the survival, expansion, and maintenance of Th17 cellular populations. In a landmark case-control study, researchers evaluated serum cytokine concentrations in forty-nine patients presenting with palmoplantar or anogenital verrucae alongside forty-one healthy controls. Serum analysis revealed that median IL-23 levels were significantly elevated in patients with warts compared to healthy individuals. Specifically, the median IL-23 level reached 11.8 pg/mL in the patient group, whereas controls exhibited a median level of 8.8 pg/mL. Statistical analysis confirmed this difference as highly significant, demonstrating a clear systemic upregulation of IL-23 during active infection. This elevation indicates that cutaneous verrucae trigger broader systemic immune signaling rather than remaining entirely isolated within local epidermal tissue. Interleukin-23 production by antigen-presenting cells likely reflects ongoing immune activation in response to viral antigens. Consequently, measuring IL-23 in cutaneous verrucae establishes a measurable systemic biomarker reflecting underlying host Th17 pathway engagement during active human papillomavirus infection.

Comparing Serum IL-17A and Interleukin-23 Levels

Although IL-23 levels demonstrated a statistically significant elevation, comparative analysis of downstream interleukin-17A revealed contrasting patterns. The study documented a median serum IL-17A level of 16.6 pg/mL among affected patients, compared to 16.4 pg/mL within the control cohort. Statistical testing demonstrated no significant difference between the two groups regarding circulating IL-17A levels. This observation suggests that systemic concentrations of IL-17A remain relatively stable despite elevated upstream IL-23 signaling. However, correlation analysis revealed a strikingly strong positive relationship between IL-17A and IL-23 concentrations specifically within the patient group. This robust correlation indicates functional coupling between these two cytokines during human papillomavirus infection. While systemic IL-17A levels do not show overt baseline elevation, local tissue expression within infected epidermal layers might still be markedly altered. Furthermore, systemic regulation of IL-17A could be tightly controlled by compensatory counter-regulatory mechanisms. Therefore, interpreting serum cytokine profiles requires evaluating both upstream drivers and downstream effector proteins in tandem rather than relying on single isolated parameters.

Correlations Between Cytokines and Clinical Parameters

To determine whether systemic cytokine levels correlate with clinical severity, investigators evaluated several patient parameters. These variables included patient age, biological sex, total lesion count, overall disease duration, and anatomical lesion localization. Interestingly, statistical evaluation revealed no significant correlation between serum IL-23 or IL-17A levels and these specific clinical features. Neither disease duration nor the anatomical location of warts significantly altered circulating cytokine concentrations. Additionally, total lesion burden failed to demonstrate a direct proportional relationship with systemic interleukin levels. These findings imply that systemic immune activation occurs independently of visible disease extent or duration. Consequently, serum cytokine elevations appear to reflect intrinsic host immune responses to viral antigens rather than simply mirroring total viral load or physical lesion area. Furthermore, these results suggest that systemic cytokine measurements provide unique immunologic data that clinical physical examination alone cannot capture. Understanding these biological dynamics helps dermatologists contextualize systemic host responses in routine clinical management.

Clinical Implications for HPV Infection Management

Identifying alterations in the IL-23/IL-17 axis offers valuable clinical implications for understanding human papillomavirus pathobiology. Elevated serum IL-23 demonstrates that local cutaneous verrucae provoke measurable systemic immune responses. This systemic involvement highlights the complex interplay between mucosal, cutaneous, and peripheral circulating immune components. Furthermore, recognizing the strong correlation between IL-23 and IL-17A reinforces the clinical relevance of Th17-mediated pathways in viral skin diseases. While conventional therapies focus primarily on localized lesion destruction through cryotherapy, topical keratolytics, or electrosurgery, emerging research suggests systemic immunomodulation might offer adjunctive therapeutic value. Patients suffering from recalcitrant, extensive, or recurrent warts could potentially benefit from strategies targeting host immune signaling pathways. Moreover, detailed cytokine profiling enhances risk stratification and personalized management plans for complex HPV cases. As research continues to elucidate cytokine networks, clinicians will gain deeper insights into host susceptibility, viral persistence, and novel immunotherapeutic avenues for recalcitrant verrucae.

Future Perspectives in Cytokine Research and Diagnostics

Future clinical investigation must expand upon these foundational findings to clarify exact tissue-level cytokine interactions. Comparing serum cytokine concentrations directly with local epidermal tissue biopsies will help determine whether peripheral blood measurements reflect local inflammatory activity. Additionally, longitudinal studies tracking serum IL-23 levels before and after successful clinical treatment could evaluate its utility as a therapeutic response biomarker. Furthermore, exploring cytokine expression across broader patient populations, including immunocompromised individuals, will enhance clinical generalizability. As diagnostic technologies advance, enzyme-linked immunosorbent assays and multiplex cytokine panels may become valuable adjuncts in complex dermatological assessments. Ultimately, advancing our understanding of systemic cytokine dynamics in human papillomavirus infection bridges basic immunology with clinical practice, driving better patient outcomes.

Frequently Asked Questions

What is the primary role of IL-23 in cutaneous verrucae infection?

Interleukin-23 acts as a key upstream cytokine that promotes the survival and expansion of T helper 17 cells. In patients with cutaneous verrucae, elevated serum IL-23 levels indicate systemic immune activation in response to human papillomavirus. This systemic response helps coordinate inflammatory signaling and host defense mechanisms against viral persistence within epidermal keratinocytes, offering crucial insight into host-pathogen immunodynamics.

Does serum IL-17A significantly differ between wart patients and controls?

Clinical study results show that serum IL-17A levels do not differ significantly between patients with cutaneous verrucae and healthy control subjects. However, a strong positive correlation exists between IL-17A and IL-23 levels in affected patients. This finding suggests that while circulating IL-17A remains baseline, its regulation is closely linked to upstream IL-23 signaling during active human papillomavirus infection.

Are serum IL-23 levels correlated with wart duration or lesion number?

Statistical analysis indicates no significant correlation between serum IL-23 levels and clinical parameters such as disease duration, total lesion count, patient age, or lesion localization. Systemic cytokine elevation occurs independently of physical disease extent. Therefore, serum IL-23 reflects intrinsic host immune activation rather than directly mirroring total physical wart burden or duration of viral exposure.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Yildirim H et al. The IL-23/IL-17Axis in cutaneous verrucae: evidence from serum cytokine analysis in HPV infection. Cytokine. 2026 Aug 05. doi: undefined. PMID: 42556008.
2. Marie RE et al. Interleukins in the Pathogenesis of Warts: Insight from the Last Decade—A Narrative Review. J Clin Med. 2025;14(2):450-462.
3. Khare P et al. Role of interleukin-17 in human papillomavirus infection and associated malignancies. Microb Pathog. 2021;161(Pt A):105294.